1Messori A, Vaiani M, Trippoli S, et al. Survival in patients with intermediate or high grade non-Hodgkin' s lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP [J]. Br J Cancer, 2001,84(3) :303-307.
2Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase Ⅱ trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas [J]. Ann Oncol, 1995,6(6) :609-611.
2Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimen for advanced non-Hodgkin's lymphoma [J]. N Engl J Med, 1993,328(14): 1002-1006.
3Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) [J]. Blood,1988,71 ( 1 ): 117-122.
4Coleman M, Leonard J, Shuster MW, et al. DICE(dexamethasone, ifosfamide, cisplatine, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin'slymphoma (NHL) [J]. Eur J Haematol, 2001,64:41-45.
5Wilder DD, Ogden JL, Jain VK, et al. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma [J]. Clin Lymphoma, 2001,1 (4): 285-292.
6Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase Ⅱ trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas [ J ]. Ann Oncol, 1995,6 (6): 609-611.
7The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma [J]. N Engl J Med, 1993,329(14):987-993
8Mayer J, Vasova I, Koristek Z, et al. Ifosfamide- and etoposidebased chemotherapy as salve and mobilizing regimens for poorprognosis lymphoma [ J ]. Eur J Haematol Suppl, 2001,64: 21 -27.
9Emmanouilides C, Lill M, Telatar M, et al. Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma [J]. Clin Lymphoma, 2002,3 (2): 111 - 116.
6Oyan B,Koc Y,Ozdemir E,et al.Ifosfamide idarubicin and etoposide in relapsed refractory Hodgkin disease or non Hodgkin lymphoma asalvage regimen with high response rates before autologous stem cell transplantation[J].J Biol Blood Marrow Transplant,2005,11(9):688.
7Jo JC,Kang BW,Jang G,et al.BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hedskin's lymphoma patients:comparative analysis of efficacy and toxicity[J].Ann Hematol,2008,87(1):43.
8Berdeja JG,Hess A,Lucas DM,et al.Systemic interleukin-2 and adoptive transfer of lymphokine-activatad killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab[J].Clin Cancer Res,2007,13(8):2392.
9Rodriguez J,Conde E,Gutierrez A,et al.The adjusted International Prognostic Index and beta-2-micrnglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma[J].Haemotologica,2007,92(8):1067.
10Messori A, Vaiani M,Trippoli S,et al. Survival in patients with intermediate or high grade non-Hodgkin's lym- phoma:Meta-analysis of randomized studies comparing third generation regimens with CHOP[J]. Br J Cancer,2001,84(3):303-307.
